Due to the plethora of studies concerning HER2 and its actionable therapy in NSCLC, only the published trials in the last 10 years enrolling more than 20 patients are reported with descriptions of the available drugs for HER2 mutations, gene amplifications, and protein overexpression (Table 2) [26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47]. Here, ERBB2 is linked to non-small cell lung carcinoma.